It is possible, therefore, that mutations or loss of mtDNA observed in human lines and patient tissues accrue over several time upon the initial FH loss, and that these defects are selected to induce a more malignant glycolytic phenotype during tumour progression. This evidence concerns the gene FH and neoplasm.